Open AccessThis article is
- freely available
Biomedicines—Moving Biologic Agents into Approved Treatment Options
Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W, Walnut Street Room 130, Indianapolis, IN 46202, USA
Received: 8 March 2013; Accepted: 8 March 2013 / Published: 11 March 2013
Abstract: The development of biologic agents for therapeutic purposes, or biomedicines, has seen an active area of research both at the bench and in clinical trials. There is mounting evidence that biologic products can provide effective therapy for diseases that have been unresponsive to traditional pharmacologic approaches. Monoclonal antibody therapy for cancer and rheumatologic diseases has become a well accepted part of disease treatment plans. Gene therapy products have been approved in China and Europe. Bioengineering of new agents capitalizing on microRNA biology, nanoparticle technology, stem cell biology, and an increasing understanding of immunology predict a rich future for product development.
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Cornetta, K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines 2013, 1, 1-2.
Cornetta K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines. 2013; 1(1):1-2.
Cornetta, Kenneth. 2013. "Biomedicines—Moving Biologic Agents into Approved Treatment Options." Biomedicines 1, no. 1: 1-2.